breast cancer

[Merck & Co., Inc.] AstraZeneca and Merck announced that LYNPARZA has been approved by the FDA for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy.

[NPJ Regenerative Medicine] To examine the effects of chronic 4-hydroxytamoxifen treatment, researchers used state-of-the-art human-induced pluripotent stem cell-derived cardiomyocytes and a bioengineered platform to model duchenne muscular dystrophy.

[Molecular Therapy-Nucleic Acids] To determine whether skeletal muscle miR-486 was functionally similar in dystrophies and cancer, the authors performed functional limitations and biochemical studies of skeletal muscles of MMTV-Neu mice that mimicked HER2+ breast cancer and MMTV-PyMT mice that mimicked luminal subtype B breast cancer.

[Oncogene] The authors observed that chromodomain Y-like 2 (CDYL2) was down-regulated in human primary HCC tissues and the low levels of CDYL2 expression were correlated with poor survival.

[Nature Communications] Investigators proposed a nanofibrillar hydrogel for the initiation and growth of breast cancer patient-derived tumor organoids.

[Cytometry Part A] Researchers developed a rapid semi-quantitative method for in situ imaging of bacteria and multiplex cell phenotypes on the same solid tumor tissue sections.